The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (MAYARI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05468320
Recruitment Status : Recruiting
First Posted : July 21, 2022
Last Update Posted : May 10, 2024
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

This is a single group, treatment, Phase 3, open-label, single-arm study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy (IST) without firstline therapeutic plasma exchange (TPE) with primary endpoint of remission in male and female participants aged 18 to 80 years with immune-mediated thrombotic thrombocytopenic purpura (iTTP).

The anticipated study duration per participant without a recurrence while on therapy is maximum 24 weeks (ie, approximately 1 day for screening + maximum 12 weeks of treatment for the presenting episode + 12 weeks of follow-up). Participants will have daily assessments during hospitalization and weekly visits for assessments during ongoing treatment with caplacizumab and IST. There will be 3 outpatient visits for assessments during the follow-up period. There will be two additional follow-up visits for participants who do not have ADAMTS13 activity levels of ≥50% at the time of caplacizumab discontinuation.


Condition or disease Intervention/treatment Phase
Thrombotic Thrombocytopenic Purpura Drug: Caplacizumab Drug: Corticosteroids Biological: anti-CD20 antibody Phase 3

Detailed Description:
The anticipated study duration per participant with the presenting episode therefore is a maximum of about 24 weeks (ie, 1 day of screening + maximum 12 weeks of treatment for the presenting episode + 12 weeks of follow-up).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 61 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
Actual Study Start Date : November 21, 2022
Estimated Primary Completion Date : December 13, 2024
Estimated Study Completion Date : December 13, 2024


Arm Intervention/treatment
Experimental: Caplacizumab & immunosuppressive therapy without 1st-line TPE
All participants will receive open label caplacizumab daily and immunosuppressive therapy (corticosteroid +/-anti-CD20 therapy antibody [rituximab or biosimilar]) without first line TPE
Drug: Caplacizumab
Lyophilized powder for solution for injection.
Other Name: Cablivi®

Drug: Corticosteroids
Solution for injection or Tablet
Other Name: Prednisone® /Prednisolone®

Biological: anti-CD20 antibody
Solution for injection
Other Name: rituximab or biosimilar




Primary Outcome Measures :
  1. Proportion of participants achieving Remission without requiring therapeutic plasma exchange (TPE). [ Time Frame: Overall study period from day 1 to day 168 (treatment period + 12 weeks of follow-up) ]
    Remission is defined as sustained Clinical Response (sustained platelet count ≥150 x 10^9/L and lactate dehydrogenase [LDH] <1.5 x upper limit of normal [ULN] and no clinical evidence of new or progressive ischemic organ injury for at least 2 consecutive visits) with either (a) no TPE and no anti- von Willebrand factor (anti-vWF) therapy for ≥ 30 days (Clinical Remission), or (b) with attainment of a disintegrin and metalloproteinase with a thrombospondin type 1 motif13 (ADAMTS13) ≥ 50% (Complete ADAMTS13 remission), whichever occurs first


Secondary Outcome Measures :
  1. Proportion of participants achieving Remission [ Time Frame: Overall study period from day 1 to day 168 ]
  2. Proportion of participants who require TPE [ Time Frame: On-treatment period from day 1 to day 84 ]
  3. The occurrence of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) [ Time Frame: Treatment-emergent (TE) period from day 1 to day 112 ]
  4. Proportion of participants achieving Clinical Response [ Time Frame: On-treatment period from day 1 to day 84 ]
    Clinical Response is defined as sustained platelet count ≥150 x 10^9/L and LDH <1.5 x ULN and no clinical evidence of new or progressive ischemic organ injury for at least 2 consecutive visits.

  5. Proportion of participants achieving Clinical Response [ Time Frame: Overall study period from day 1 to day 168 ]
  6. Time to platelet count response [ Time Frame: From day 1 to day 168 ]
    Platelet count response defined as time from start of treatment to initial platelet count ≥150 x 10^9/L that is sustained for ≥2 days

  7. Proportion of participants refractory to therapy [ Time Frame: On-treatment period from day 1 to day 84 ]
    Refractory to therapy defined as lack of sustained platelet count increment (over 2 consecutive days) or platelet counts <50 x10^9/L and persistently elevated LDH (>1.5 x ULN) despite 5 days of treatment

  8. Proportion of participants with TTP-related death [ Time Frame: On-treatment period from day 1 to day 84 ]
  9. Proportion of participants with TTP-related death [ Time Frame: Overall study period from day 1 to day 168 ]
  10. Proportion of participants with a clinical exacerbation of iTTP [ Time Frame: On-treatment period from day 1 to day 84 ]
    Clinical Exacerbation is defined as after a Clinical Response and before a Clinical Remission, platelet count decreases to <150 x 10^9/L (with other causes of thrombocytopenia excluded), with or without clinical evidence of new or progressive ischemic organ injury, within 30 days of stopping TPE or anti vWF therapy.

  11. Proportion of participants with a clinical exacerbation of iTTP [ Time Frame: Overall study period from day 1 to day 168 ]
  12. Proportion of participants with a clinical relapse of iTTP [ Time Frame: On-treatment period from day 1 to day 84 ]
    Clinical Relapse is defined as after a Clinical Remission, platelet count decreases to <150 x 10^9/L (with other causes of thrombocytopenia ruled out), with or without clinical evidence of new ischemic organ injury. A Clinical Relapse must be confirmed by documentation of severe ADAMTS13 deficiency (<10%).

  13. Proportion of participants with a clinical relapse of iTTP [ Time Frame: Overall study period from day 1 to day 168 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants with a clinical diagnosis of iTTP (initial or recurrent), which includes thrombocytopenia, microangiopathic hemolytic anemia (eg, presence of schistocytes in peripheral blood smear) and relatively preserved renal function. The iTTP diagnosis should be confirmed by ADAMTS13 testing within 48 hours (2 days).

Participants with a clinical diagnosis of iTTP and a French TMA score of 1 or 2.

A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

  • Is a woman of nonchildbearing potential (WONCBP), OR
  • Is a woman of childbearing potential (WOCBP) and agrees to use an acceptable contraceptive method during the overall treatment period and for at least 2 months after the last study drug administration.

Male participants with female partners of childbearing potential must agree to follow the contraceptive guidance as per protocol during the overall treatment period and for at least 2 months after last study drug administration.

Exclusion Criteria:

Platelet count ≥100 x 10^9/L. Serum creatinine level >2.26 mg/dL (200 µmol/L) in case platelet count is >30 x 10^9/L (to exclude possible cases of atypical HUS).

Known other causes of thrombocytopenia including but not limited to:

  • Clinical evidence of enteric infection with E. coli 0157 or related organism.
  • Atypical HUS.
  • Hematopoietic stem cell, bone marrow or solid organ transplantation-associated thrombotic microangiopathy.
  • Known or suspected sepsis.
  • Diagnosis of disseminated intravascular coagulation. Congenital TTP (known at the time of study entry). Clinically significant active bleeding or known co-morbidities associated with high risk of bleeding (excluding thrombocytopenia).

Inherited or acquired coagulation disorders. Malignant arterial hypertension. Participants requiring or expected to require invasive procedures immediately (eg, stroke requiring thrombolytic therapy, those who need mechanical ventilation, etc.).

Those presenting with severe neurological or cardiac disease. Clinical condition other than that associated with TTP, with life expectancy <6 months, such as end-stage malignancy.

Known chronic treatment with anticoagulants and anti-platelet drugs that cannot be stopped (interrupted) safely, including but not limited to:

  • vitamin K antagonists.
  • direct-acting oral anticoagulants.
  • heparin or low molecular weight heparin (LMWH).
  • non-steroidal anti-inflammatory molecules other than acetyl salicylic acid. Participants who were previously enrolled in this clinical study (study EFC16521).

Participants who received an investigational drug, or device, other than caplacizumab, within 30 days of anticipated IMP administration or 5 half-lives of the previous investigational drug, whichever is longer.

Positive result on COVID test.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05468320


Contacts
Layout table for location contacts
Contact: Trial Transparency email recommended (Toll free for US & Canada) 800-633-1610 ext option 6 contact-us@sanofi.com

Locations
Show Show 53 study locations
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT05468320    
Other Study ID Numbers: EFC16521
U1111-1244-0426 ( Registry Identifier: ICTRP )
2024-513262-19 ( Registry Identifier: CTIS )
2022-001177-31 ( EudraCT Number )
First Posted: July 21, 2022    Key Record Dates
Last Update Posted: May 10, 2024
Last Verified: May 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombotic Thrombocytopenic
Blood Coagulation Disorders
Hematologic Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations
Thrombotic Microangiopathies
Thrombocytopenia
Blood Platelet Disorders
Cytopenia
Immune System Diseases
Thrombophilia
Prednisone
Prednisolone
Antibodies
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal